These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1019 related articles for article (PubMed ID: 30729499)
1. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499 [TBL] [Abstract][Full Text] [Related]
2. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis. Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461 [TBL] [Abstract][Full Text] [Related]
3. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290 [TBL] [Abstract][Full Text] [Related]
4. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). Silverberg JI; Leshem YA; Calimlim BM; McDonald J; Litcher-Kelly L Curr Med Res Opin; 2023 Oct; 39(10):1289-1296. PubMed ID: 37691437 [TBL] [Abstract][Full Text] [Related]
5. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Kimball AB; Naegeli AN; Edson-Heredia E; Lin CY; Gaich C; Nikaï E; Wyrwich K; Yosipovitch G Br J Dermatol; 2016 Jul; 175(1):157-62. PubMed ID: 26852717 [TBL] [Abstract][Full Text] [Related]
6. Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale. Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E J Patient Rep Outcomes; 2024 Jul; 8(1):77. PubMed ID: 39039395 [TBL] [Abstract][Full Text] [Related]
7. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772 [TBL] [Abstract][Full Text] [Related]
8. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis. Puelles J; Fofana F; Rodriguez D; Silverberg JI; Wollenberg A; Dias Barbosa C; Vernon M; Chavda R; Gabriel S; Piketty C Br J Dermatol; 2022 Feb; 186(2):285-294. PubMed ID: 34608623 [TBL] [Abstract][Full Text] [Related]
9. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791 [No Abstract] [Full Text] [Related]
10. Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis. Paller AS; Yosipovitch G; Weidinger S; DiBenedetti D; Whalley D; Gadkari A; Guillemin I; Zhang H; Eckert L; Chao J; Bansal A; Chuang CC; Delevry D Dermatol Ther (Heidelb); 2022 Dec; 12(12):2839-2850. PubMed ID: 36269504 [TBL] [Abstract][Full Text] [Related]
11. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257 [TBL] [Abstract][Full Text] [Related]
12. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus. Vernon MK; Swett LL; Speck RM; Munera C; Spencer RH; Wen W; Menzaghi F J Patient Rep Outcomes; 2021 Dec; 5(1):134. PubMed ID: 34952964 [TBL] [Abstract][Full Text] [Related]
13. Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials. Kwatra SG; Yosipovitch G; Kim B; Stander S; Rhoten S; Ivanescu C; Haeusler N; Brookes E; Msihid J; Makhija M; Bansal A; Thomas RB; Bahloul D JAMA Dermatol; 2024 Aug; 160(8):813-821. PubMed ID: 38865146 [TBL] [Abstract][Full Text] [Related]
14. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial. Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233 [TBL] [Abstract][Full Text] [Related]
15. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD. Paller AS; Gonzalez ME; Barnum S; Jaeger J; Shao L; Ozturk ZE; Korotzer A Arch Dermatol Res; 2024 Jul; 316(8):497. PubMed ID: 39080094 [TBL] [Abstract][Full Text] [Related]
16. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes. Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933 [TBL] [Abstract][Full Text] [Related]
17. Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740 [TBL] [Abstract][Full Text] [Related]
18. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1. Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473 [TBL] [Abstract][Full Text] [Related]
19. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208 [TBL] [Abstract][Full Text] [Related]
20. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]